NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease

CompletedN/A

Sponsor: AstraZeneca

Conditions: Chronic Kidney Disease

Countries: United States, Australia, Brazil, Canada, China, France, Germany, Italy

This is a retrospective, multinational, non-interventional, observational study. A series of cohort studies will be conducted to assess the prevalence of undiagnosed stage 3 CKD in each region. The study will also assess the current state of CKD management in patients with undiagnosed CKD

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* At least two consecutive eGFR laboratory tests with values ≥30 and \<60 mL/min/1.73 m2 (Stage 3A or 3B) that are \>90 and ≤730 days apart. The index date is the date of the second eGFR measure meeting the criteria for stage 3 CKD
* At least 12 months of continuous presence in the database or registration in the data prior to the first qualifying eGFR (for data sources with information on enrolment)
* Age ≥18 years at index date

Exclusion Criteria:

* Solid organ transplant before the study index date
* Any evidence of advanced CKD (stage 4, 5) based on CKD diagnostic codes, or renal replacement therapy before the index date

Locations (13)

Louisville, Kentucky, United States
Cambridge, Massachusetts, United States
Ann Arbor, Michigan, United States
Sydney, New South Wales, Australia
São Paulo, Brazil
Kingston, Ontario, Canada
Guangzhou, Guangdong, China
Boulogne-Billancourt, France
Frankfurt, Germany
Milan, Italy
Kyoto, Japan
Madrid, Spain
London, Greater London, United Kingdom